Altor BioScience is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer and viral infections, based on its engineered cytokine technology platforms. It was formed in 2002 by Dr. […]
Soligenix to Present at the 2017 Biotech and Money Showcase Conference
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, recently announced that its President and Chief […]
ImmunoCellular Therapeutics’ Immune-Based Therapies for the Treatment of Cancer
Dr. Anthony Gringeri, President and CEO of Immunocellular Therapeutics, a company developing immune-based therapies for the treatment of cancer, is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells […]
TapImmune Amends Patient Inclusion Criteria for Phase 2 Clinical Trial
TapImmune (TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women’s cancers has announced that it has amended the patient inclusion criteria for its Phase 2 clinical trial of […]
Dorsey Represents Mayo Clinic’s Venture Applying AI in Drug Development
Dorsey client Mayo Clinic and Cambridge, Massachusetts-based nference recently announced the formation of Qrativ. Qrativ will combine nference’s artificial intelligence (AI) knowledge synthesis platform with Mayo Clinic’s medical expertise and clinical data […]
Soligenix Initiates Phase 3 Trial of Dusquetide for Oral Mucositis in Head & Neck Cancer Patients
Soligenix’s self-described “DOM–INNATE” study has initiated patient enrollment. The late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that patient […]
Avant Diagnostics Announces Confirmatory Clinical Utility Data for Theralink in Pancreatic Cancer
Avant Diagnostics, Inc. (‘Avant’) (OTC: AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink proteomic biomarker platform announced positive clinical utility data, the confirmation of the clinical utility of the Theralink […]
Buying Spree: Chinese FDI in Western healthcare companies
In 2016, Chinese companies invested more than $44B in the United States. The amount of investment has been growing steadily since 2000, increasing substantially each coming year. Over the last 16 years, […]
